MER 511
Alternative Names: MER-511Latest Information Update: 22 Jan 2026
At a glance
- Originator Merida Biosciences
- Class Immunoglobulin Fc fragments; Immunotherapies; Recombinant proteins
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Graves' disease
Most Recent Events
- 07 Jan 2026 Merida Biosciences has 3 patent pending applications, two for "Molecules for controlling autoimmune response" (WO 202 503 000 3A2) (WO 202 503 000 0A1) and one for "Molecules for controlling immune response" (WO 202 503 000 9A1) in the multiple countries worldwide prior to January 2026
- 08 Dec 2025 Phase-I clinical trials in Graves' disease in USA (IV) (NCT07305818)
- 08 Dec 2025 Phase-I clinical trials in Graves' disease in USA (SC) (NCT07305818)